Literature DB >> 21288830

Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?

Yoav Keynan, Jennifer Juno, Ken Kasper, Ethan Rubinstein, Keith R Fowke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21288830      PMCID： PMC3071059          DOI： 10.1093/infdis/jiq032

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  8 in total

1.  CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.

Authors:  Jean K Lim; David H McDermott; Andrea Lisco; Gregory A Foster; David Krysztof; Dean Follmann; Susan L Stramer; Philip M Murphy
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

2.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

4.  The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections.

Authors:  Jacob E Kohlmeier; Shannon C Miller; Joanna Smith; Bao Lu; Craig Gerard; Tres Cookenham; Alan D Roberts; David L Woodland
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

5.  Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.

Authors:  Jean K Lim; Christine Y Louie; Carol Glaser; Cynthia Jean; Bernard Johnson; Hope Johnson; David H McDermott; Philip M Murphy
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

6.  A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis.

Authors:  Elin Kindberg; Aukse Mickiene; Cecilia Ax; Britt Akerlind; Sirkka Vene; Lars Lindquist; Ake Lundkvist; Lennart Svensson
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

7.  Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

Authors:  Jamal Suleiman; Barry S Zingman; Ricardo Sobhie Diaz; Jose Valdez Ramalho Madruga; Edwin DeJesus; Jihad Slim; Carmen Mak; Erin Lee; Michael C McCarthy; Lisa M Dunkle; Sharon Walmsley
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

8.  Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.

Authors:  William G Glass; Jean K Lim; Rushina Cholera; Alexander G Pletnev; Ji-Liang Gao; Philip M Murphy
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.